Loading
A phase 1/2 trial of Linvoseltamab in multiple myeloma, run by Regeneron Pharmaceuticals, now recruiting.
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT07455851 by Regeneron Pharmaceuticals, with 150 participants planned, started 2026-03-26 and due to reach its primary completion in 2033-09-30. Interventions recorded: Linvoseltamab, REGN17372+Linvoseltamab. Conditions listed: Relapsed Refractory Multiple Myeloma (RRMM). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, T-cell engagers (bispecific), Multiple myeloma.
Shares Linvoseltamab, Regeneron, Relapsed or refractory multiple myeloma, T-cell engagers (bispecific).
Shares Relapsed or refractory multiple myeloma, T-cell engagers (bispecific), Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/